After PS matching and adjustment for statin use, age, sex, urbanization, income, DM, hypertension, stroke, CAD, COPD, smoking-related disorders, CT/RT, EGFR-TKI response, and regimens before EGFR-TKI therapy (S2 Table), a reduced risk of death was still observed in statin users (HR: 0.61, 95% CI: 0.57–0.65, p < 0.001), those with monthly income ≧25000 NT$ (HR: 0.78, 95% CI: 0.70–0.87, p < 0.001), EGFR-TKI responder (HR: 0.41, 95% CI: 0.38–0.43, p < 0.001), and ≥2 CT regimens before EGFR-TKI (HR: 0.91, 95% CI: 0.85–0.97, p = 0.004) (S2 Table). This evidence concerns the gene EGFR and stroke disorder.